Aim: To compare the efficacy of postoperative topical nepafenac (0.1%) with prednisolone acetate (1%) as anti-inflammatory agents in eyes undergoing Transscleral Sutureless Vitrectomy (TSV).
Settings And Design: Prospective, double-blind, randomized, single center clinical study.
Materials And Methods: Eighty eyes of 76 subjects, who underwent small gauge vitrectomy, were included in the study. The subjects who fulfilled the inclusion criteria were randomized to either topical nepafenac only (Group 1) or prednisolone acetate only (Group 2), to be used as postoperative anti-inflammatory agents. The subjects were reviewed on days 1, 30, and 90. Ocular and adnexal inflammation was appropriately graded using the standardized classification. Grading of ocular pain was done on the Visual Analog Scale (VAS).
Statistical Analysis: The Wilcoxon rank-sum test, using two-sided analysis, was used.
Results: During the follow-up, both Group 1 and Group 2 did not have a significant difference related to the grade of the anterior chamber inflammation (P > 0.05) or adnexal inflammation (P > 0.05). Pain perception was less in the subjects in Group 1 as compared to subjects in Group 2, but was not statistically significant (P > 0.05).
Conclusion: Postoperative topical nepafenac was non-inferior to prednisolone acetate in reducing postoperative ocular inflammation in eyes undergoing TSV.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065514 | PMC |
http://dx.doi.org/10.4103/0301-4738.129781 | DOI Listing |
Oman J Ophthalmol
June 2024
Regional Institute of Ophthalmology, Minto Ophthalmic Institute, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India.
Context: Diabetic eyes suffer from variety of complications including macular edema. Cataract surgery is the most commonly done procedure throughout the world and majority would be diabetics. As pseudophakic-cystoid macular edema (CME) is a known complication following cataract surgery, our study concentrated on finding the role of prophylactic topical nonsteroidal anti-inflammatory drugs (NSAIDs) on change in total macular volume (TMV) postcataract surgery in diabetic eyes.
View Article and Find Full Text PDFEye (Lond)
December 2024
Department of Ophthalmology, "Iuliu Hatieganu" University of Medicine and Pharmacy, ClujNapoca, 400394, Romania.
The aim of this Network Meta-analysis was to compare the efficacy of the different topical Nonsteroidal anti-inflammatory drugs (NSAIDs) when added or not to topical steroids in preventing the thickening of the macula and their impact on visual acuity and intraocular pressure after phacoemulsification. Five electronic databases were searched, including PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov.
View Article and Find Full Text PDFEur J Ophthalmol
July 2024
Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel.
Purpose: This case report aims to report the development of cystoid macular edema (CME) unilaterally following the administration of bimatoprost implant (Durysta) injections in both eyes for the treatment of primary open-angle glaucoma (POAG).
Observations: An 84-year-old female patient, previously diagnosed with POAG, underwent bimatoprost implant (Durysta) injections in both eyes, spaced one month apart. Subsequently, the patient experienced a gradual decline in visual acuity in her left eye attributed to the development of CME.
Retina
July 2024
Trakya University School of Medicine, Department of Ophthalmology, Edirne, Turkey; and.
Purpose: To compare topical nonsteroidal anti-inflammatory drug (NSAID) efficacy on intravitreal injection-induced pain reduction and determine the most efficient topical NSAID.
Methods: This randomized-controlled study included 662 eyes of 662 patients. Based on the types of NSAID administered before intravitreal injection, eight subgroups were formed.
Int J Retina Vitreous
September 2023
Centro Brasileiro da Visao, Brasilia, DF, Brazil.
Background: The purpose of this study was to compare the impact of intravitreal dexamethasone (DEX) implant during a 12-month period in nondiabetic and diabetic patients without diabetic retinopathy (DR) as a treatment for refractory pseudophakic cystoid macular edema (PCME) following prior treatment with topical nepafenac 0.1% and prednisolone 1%.
Methods: Forty-two consecutive medical records of patients diagnosed with PCME after uneventful cataract surgery were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!